title: A second extracellular site is required for norepinephrine transport by the human norepinephrine transporter.
abstract: The human norepinephrine transporter (NET) is implicated in many neurological disorders and is a target of tricyclic antidepressants and nisoxetine (NX). We used molecular docking simulations to guide the identification of residues likely to affect substrate transport and ligand interactions at NET. Mutations to alanine identified a hydrophobic pocket in the extracellular cavity of NET, comprising residues Thr80, Phe317, and Tyr317, which was critical for efficient norepinephrine (NE) transport. This secondary NE substrate site (NESS-2) overlapped the NX binding site, comprising Tyr84, Phe317, and Tyr317, and was positioned ∼11 Å extracellular to the primary site for NE (NESS-1). Thr80 in NESS-2 appeared to be critical in positioning NE for efficient translocation to NESS-1. Three residues identified as being involved in gating the reverse transport of NE (Arg81, Gln314, and Asp473) did not affect NE affinity for NESS-1. Mutating residues adjacent to NESS-2 abolished NET expression (D75A and L76A) or appeared to affect NET folding (S419A), suggesting important roles in stabilizing NET structure, whereas W308A and F388A at the top of NESS-2 abolished both NE transport and NX binding. Our findings are consistent with a multistep model of substrate transport by NET, for which a second, shallow extracellular NE substrate site (NESS-2) is required for efficient NE transport by NET.
authors.affiliation: Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Brisbane, Queensland, Australia.
authors.forename: Ching-I A
authors.initials: CI
authors.lastname: Wang
authors.forename: Nausad H
authors.initials: NH
authors.lastname: Shaikh
authors.forename: Soumya
authors.initials: S
authors.lastname: Ramu
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Lewis
mesh_terms: D018759:Adrenergic Uptake Inhibitors / Q000378:metabolism; D000818:Animals; D001665:Binding Sites; D001692:Biological Transport; D019556:COS Cells; D002522:Chlorocebus aethiops; D003198:Computer Simulation; D005473:Fluoxetine / Q000031:analogs & derivatives / Q000378:metabolism; D006801:Humans; D007930:Leucine / Q000737:chemistry / Q000378:metabolism; D062105:Molecular Docking Simulation; D016297:Mutagenesis, Site-Directed; D009638:Norepinephrine / Q000737:chemistry / Q000378:metabolism*; D050484:Norepinephrine Plasma Membrane Transport Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
chemical_list: D018759:Adrenergic Uptake Inhibitors; D050484:Norepinephrine Plasma Membrane Transport Proteins; D005473:Fluoxetine; C011386:nisoxetine; D007930:Leucine; D009638:Norepinephrine